SureNano Science Acquires GlucaPharm to Advance Next-Generation Obesity Treatment

Vancouver, British Columbia – February 23, 2026 – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has completed the acquisition of GlucaPharm Inc., a pharmaceutical company developing a novel peptide, GEP44, for the treatment of obesity and metabolic disease. The acquisition aims to accelerate SureNano’s transition into a pharmaceutical company focused on innovative metabolic therapies.

GEP44: A Potential Improvement Over Existing GLP-1 Drugs

GlucaPharm’s lead therapeutic candidate, GEP44, is a patented peptide discovered by researchers at Syracuse University. It functions similarly to established drugs like Ozempic®, Wegovy® and Mounjaro®, but preclinical studies suggest it may offer a reduced risk of adverse events . These existing GLP-1 receptor agonists have demonstrated significant efficacy in weight management and blood glucose control, but can be associated with gastrointestinal side effects.

Strategic Acquisition for SureNano

The acquisition of GlucaPharm strengthens SureNano’s platform and aligns with its strategy of developing next-generation solutions that improve therapeutic performance, tolerability, and delivery . According to Charles MaLette, CEO of SureNano Science Ltd., the acquisition positions the company to participate meaningfully in the rapidly growing GLP-1 metabolic market .

Financial Details of the Acquisition

The transaction was structured as a share exchange, with SureNano issuing 8,100,999 common shares to GlucaPharm shareholders and warrants to purchase 5,000,000 common shares to the holder of GlucaPharm warrants . The shares issued are subject to a hold period pending approval from the Canadian Securities Exchange and the release of SureNano’s 2026 audited financial statements . SureNano recently completed $1.25 million in financing to support the development of GEP44 .

Future Development Plans

GlucaPharm is currently advancing GEP44 in collaboration with an Australian contract research organization (CRO). An Investigational New Drug (IND)-enabling study is underway, with a Phase I Clinical Trial expected to commence in Australia in the coming months . The company is also exploring non-injectable administration routes, including oral, sublingual, or nasal delivery, which could broaden patient access and improve adherence .

Dr. Nihar R. Pandey Appointed Chief Scientific Officer

SureNano has appointed Dr. Nihar R. Pandey as Director and Chief Scientific Officer. Dr. Pandey brings 25 years of experience in drug discovery and development, with a Ph.D. In Clinical Biochemistry .

Disclaimer: This article is based on publicly available information as of March 17, 2026, and should not be considered medical advice.